Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-06-18

Metagenomics in Cardiometabolic Diseases

Objectif

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.

METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.

We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2012-INNOVATION-1
Voir d’autres projets de cet appel

Régime de financement

CP-IP - Large-scale integrating project

Coordinateur

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contribution de l’UE
€ 2 562 788,00
Adresse
RUE DE TOLBIAC 101
75654 Paris
France

Voir sur la carte
Région
Ile-de-France Ile-de-France Paris
Type d’activité
Research Organisations
Contact administratif
Akouavi Ekoue (Ms.)
Liens
Coût total
Aucune donnée

Participants (15)

Partager cette page

Télécharger

Dernière mise à jour: 6 Septembre 2024

Mon livret

Permalink: https://cordis.europa.eu/project/id/305312/fr

European Union, 2024